Table 2.

CLARITY clinical efficacy results.

	Annualized relapse rate	Relative reduction	Proportion who remained relapse free at 96 weeks	Time to first relapse Hazard ratio	Risk of 3 month sustained progression of disability
Cladribine (3.5 mg/kg)	0.14	57.6% (P < 0.001)	79.7% (P < 0.001)	0.44 (95% CI 0.34–0.58) (P < 0.001)	33% reduction (Hazard ratio 0.67, 95% CI 0.48–0.93)
Cladribine (5.25 mg/kg)	0.15	54.5% (P < 0.001)	78.9% (P < 0.001)	0.46 (95% CI 0.36–0.6) (P < 0.001)	31% reduction (Hazard ratio 0.69 95% CI 0.49–0.96)
Placebo	0.33		60.9%